HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A clinicopathological study on the expression of cadherin-17 and caudal-related homeobox transcription factor (CDX2) in human gastric carcinoma.

AbstractAIMS:
To analyse the clinicopathological characteristics of the expression of cadherin-17 (CDH17) and caudal-related homeobox transcription factor (CDX2) in human gastric carcinoma, and to evaluate the clinical significance of these two markers in the histological classification and prognosis of gastric carcinoma.
MATERIALS AND METHODS:
CDH17, CDX2 protein expression in paraffin-embedded specimens gathered from 166 patients with gastric carcinoma were detected by immunohistochemistry. The association of CDH17, CDX2 protein expression with the clinicopathological characteristics, and with the prognosis of gastric carcinoma were subsequently assessed.
RESULTS:
CDH17, nucleus and cytoplasm CDX2 expression were positively expressed in 101/166 (60.8%), 59/166 (35.5%) and 57/166 (34.3%) gastric carcinoma patients, respectively. The expression of both CDH17 and CDX2 is associated with the intestinal-type gastric carcinoma (P<0.01). Positive expression of CDH17 was significantly associated with the depth of gastric wall invasion (P=0.04), lymph node metastasis (P<0.01) and stages of gastric carcinoma (P=0.01). Positive expression of CDX2 in the nucleus was mainly found in male patients (P=0.02), in early stage (P=0.01) and medullary-type gastric carcinoma (P=0.02). There was a negative association between nuclear CDX2 expression and lymph node metastasis of gastric carcinoma (P<0.01). The combined expression of CDH17 and CDX2 was significantly lower in diffuse-type carcinoma than intestinal- or mixed-type carcinoma (P<0.01 and P=0.01, respectively). The patients with CDH17 expression associated with poor prognosis of gastric carcinoma (P<0.01), as opposed to patients with CDX2 expression (P<0.01). The survival rate of patients with CDH17+/CDX2- expression was the lowest (P<0.01), and conjoined expressions of CDH17+/CDX2- and CDH17+/CDX2+ were independent prognostic indicators of gastric carcinoma (both P<0.01).
CONCLUSION:
The results suggest that the expression of CDH17 or CDX2 may be an important feature of gastric carcinoma. A combined detection of CDH17/CDX2 co-expression may benefit us in predicting the prognosis of gastric carcinoma.
AuthorsJie Ge, Zhikang Chen, Shaobin Wu, Weijie Yuan, Bin Hu, Zihua Chen
JournalClinical oncology (Royal College of Radiologists (Great Britain)) (Clin Oncol (R Coll Radiol)) Vol. 20 Issue 4 Pg. 275-83 (May 2008) ISSN: 0936-6555 [Print] England
PMID18353622 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Biomarkers, Tumor
  • CDH17 protein, human
  • CDX2 Transcription Factor
  • CDX2 protein, human
  • Cadherins
  • Homeodomain Proteins
Topics
  • Adult
  • Aged
  • Biomarkers, Tumor (analysis)
  • CDX2 Transcription Factor
  • Cadherins (metabolism)
  • Carcinoma (metabolism, mortality, pathology)
  • Female
  • Homeodomain Proteins (metabolism)
  • Humans
  • Immunohistochemistry
  • Male
  • Middle Aged
  • Prognosis
  • Stomach Neoplasms (metabolism, mortality, pathology)
  • Survival Rate

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: